Completed PHASE2 INTERVENTIONAL 3-arm NCT00104572

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

The Effects of Aromatase Inhibition and Testosterone Replacement in Sex Steroids, Pituitary Hormones, Markers of Bone Turnover, Muscle Strength, and Cognition in Older Men

Sponsor: National Institute on Aging (NIA)

Conditions Depression Diabetes Hypogonadism Osteoporosis Sarcopenia

Interventions Anastrozole (Aromatase Inhibitor) Androgel (Testosterone Gel) Calcium Cardone 500mg with vitamin D 400 IU Placebo gel Placebo tablet

Updated 8 times since 2017 Last updated: Oct 11, 2018 Started: Mar 31, 2004 Primary completion: Dec 31, 2013 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Depression and Diabetes, this trial is completed. The trial is conducted by National Institute on Aging (NIA) and has accumulated 8 data snapshots since 2004. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2018 — Jan 2021 [monthly]

Completed PHASE2
Nov 2018 — Dec 2018 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Aging (NIA)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States